|
EP2210607B1
(en)
*
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
KR100799534B1
(ko)
|
2004-02-27 |
2008-01-31 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
신규 피리딘 유도체 및 피리미딘 유도체(1)
|
|
EP1781664B1
(en)
|
2004-07-30 |
2013-09-04 |
MethylGene Inc. |
Inhibitors of vegf receptor and hgf receptor signaling
|
|
MX2007014617A
(es)
|
2005-05-20 |
2008-02-11 |
Methylgene Inc |
Inhibidores de senalizacion de receptor de factor de crecimiento endotelial bascular y receptor de factor de crecimiento de hepatocitos.
|
|
WO2008041053A2
(en)
*
|
2005-05-20 |
2008-04-10 |
Methylgene, Inc. |
Inhibitors of vegf receptor and hgf receptor signaling
|
|
RU2007146986A
(ru)
*
|
2005-06-02 |
2009-06-27 |
ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) |
Способы лечения опухолей головного мозга с использованием антител
|
|
TWI377198B
(en)
|
2005-08-24 |
2012-11-21 |
Eisai R&D Man Co Ltd |
Novel pyridine derivatives and pyrimidine derivatives (3)
|
|
JP5102771B2
(ja)
*
|
2005-10-28 |
2012-12-19 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼとしての化合物および組成物
|
|
NL2000291C2
(nl)
|
2005-11-10 |
2009-02-17 |
Pfizer Prod Inc |
1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
|
|
US8003662B2
(en)
|
2006-01-30 |
2011-08-23 |
Array Biopharma, Inc. |
Heterobicyclic thiophene compounds and methods of use
|
|
US7723330B2
(en)
|
2006-03-07 |
2010-05-25 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
|
AR059922A1
(es)
*
|
2006-04-01 |
2008-05-07 |
Galaxy Biotech Llc |
Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
|
|
CA2651898A1
(en)
|
2006-04-07 |
2007-10-18 |
Develogen Aktiengesellschaft |
Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
|
|
US20110053931A1
(en)
*
|
2006-06-08 |
2011-03-03 |
John Gaudino |
Quinoline compounds and methods of use
|
|
EP1889847A1
(en)
|
2006-07-10 |
2008-02-20 |
DeveloGen Aktiengesellschaft |
Pyrrolopyrimidines for pharmaceutical compositions
|
|
US7683060B2
(en)
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
ATE535520T1
(de)
*
|
2006-08-23 |
2011-12-15 |
Eisai R&D Man Co Ltd |
Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung
|
|
US7790885B2
(en)
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
|
US20100016307A1
(en)
*
|
2006-10-27 |
2010-01-21 |
Toshihiro Hamajima |
Novel compounds
|
|
GEP20125658B
(en)
|
2006-11-22 |
2012-10-10 |
Incyte Corp |
Imidazotriazines and imidazo pyrimidines as kinase inhibitors
|
|
EA019941B1
(ru)
|
2006-12-08 |
2014-07-30 |
АйАрЭм ЭлЭлСи |
Соединения и композиции в качестве ингибиторов протеинкиназы
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
JP2010538094A
(ja)
*
|
2007-09-06 |
2010-12-09 |
アレイ バイオファーマ、インコーポレイテッド |
チロシンキナーゼ阻害剤としてのピラゾロピリジン類
|
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
|
MX2010009729A
(es)
|
2008-03-05 |
2010-12-21 |
Methylgene Inc |
Inhibidores de actividad de proteina tirosina quinasa.
|
|
SI2300455T1
(sl)
|
2008-05-21 |
2017-12-29 |
Incyte Holdings Corporation |
Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
|
|
RS53382B
(sr)
*
|
2008-08-20 |
2014-10-31 |
Zoetis Llc |
Jedinjenja pirol [2,3-d]pirimidina
|
|
BRPI0918971A2
(pt)
|
2008-08-26 |
2015-12-01 |
Boehringer Ingelheim Int |
tienopirimidinas para composições farmacêuticas
|
|
AU2009303602B2
(en)
*
|
2008-10-14 |
2012-06-14 |
Sunshine Lake Pharma Co., Ltd. |
Compounds and methods of use
|
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
|
TW201920110A
(zh)
|
2009-01-16 |
2019-06-01 |
美商艾克塞里克斯公司 |
包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
|
|
EP2408300B1
(en)
*
|
2009-03-21 |
2016-05-11 |
Sunshine Lake Pharma Co., Ltd. |
Amino ester derivatives, salts thereof and methods of use
|
|
EP2245936A1
(en)
|
2009-04-27 |
2010-11-03 |
Bayer CropScience AG |
Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
AU2010308028A1
(en)
*
|
2009-10-15 |
2012-04-19 |
Pfizer Inc. |
Pyrrolo[2,3-d] pyrimidine compounds
|
|
DE102009056886A1
(de)
|
2009-12-03 |
2011-06-09 |
Bayer Schering Pharma Aktiengesellschaft |
cMet-Inhibitoren zur Behandlung der Endometriose
|
|
MX2012008898A
(es)
|
2010-02-03 |
2012-11-06 |
Incyte Corp |
Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
|
|
UY33241A
(es)
|
2010-02-26 |
2011-09-30 |
Boehringer Ingelheim Int |
?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
|
|
ES2562959T3
(es)
|
2010-02-26 |
2016-03-09 |
Evotec International Gmbh |
Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
|
|
MX2012009735A
(es)
|
2010-02-26 |
2012-09-12 |
Boehringer Ingelheim Int |
4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
|
|
JP5960688B2
(ja)
|
2010-05-17 |
2016-08-02 |
インコゼン セラピューティクス プライベート リミテッド |
プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
|
|
WO2011146287A1
(en)
|
2010-05-20 |
2011-11-24 |
Takeda Pharmaceutical Company Limited |
Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5
|
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
|
WO2012009722A1
(en)
|
2010-07-16 |
2012-01-19 |
Exelixis, Inc. |
C-met modulator pharmaceutical compositions
|
|
HUE045810T2
(hu)
|
2010-09-27 |
2020-01-28 |
Exelixis Inc |
MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
|
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
|
TW201309650A
(zh)
|
2011-02-10 |
2013-03-01 |
艾克塞里克斯公司 |
製造喹啉化合物之方法及包含該化合物之醫藥組合物
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
EP2704717A1
(en)
|
2011-05-02 |
2014-03-12 |
Exelixis, Inc. |
Method of treating cancer and bone cancer pain
|
|
WO2013018929A1
(en)
|
2011-08-04 |
2013-02-07 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
MD20140023A2
(ro)
|
2011-09-22 |
2014-06-30 |
Pfizer Inc. |
Derivaţi de pirolpirimidină şi purină
|
|
GEP201606523B
(en)
|
2011-09-22 |
2016-08-10 |
Exelixis Inc |
Method for treating osteoporosis
|
|
PL2768796T3
(pl)
*
|
2011-10-20 |
2020-05-18 |
Exelixis, Inc. |
Sposób wytwarzania pochodnych chinoliny
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CA2861010A1
(en)
|
2012-01-13 |
2013-07-18 |
Xiao Xu |
Heterocyclic compounds and uses as anticancer agents
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
CN104321322A
(zh)
|
2012-03-30 |
2015-01-28 |
理森制药股份公司 |
作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
HK1207587A1
(en)
|
2012-05-02 |
2016-02-05 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
TWI520962B
(zh)
*
|
2012-06-29 |
2016-02-11 |
貝達藥業股份有限公司 |
As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
|
|
CN103570723B
(zh)
*
|
2012-07-27 |
2016-07-13 |
广西梧州制药（集团）股份有限公司 |
吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
|
|
CA2889572C
(en)
|
2012-11-08 |
2019-03-05 |
Pfizer Inc. |
Heteroaromatic compounds as dopamine d1 ligands
|
|
CN102964308B
(zh)
*
|
2012-11-30 |
2015-03-18 |
中国药科大学 |
新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
|
JPWO2014098176A1
(ja)
|
2012-12-21 |
2017-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
|
GEP20196995B
(en)
|
2013-03-15 |
2019-07-25 |
Inc Exelixis |
Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
|
|
EP2983639A1
(en)
*
|
2013-04-04 |
2016-02-17 |
Exelixis, Inc. |
Drug combinations to treat cancer
|
|
ES2927651T3
(es)
|
2013-04-04 |
2022-11-10 |
Exelixis Inc |
Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
|
|
CA2912219C
(en)
|
2013-05-14 |
2021-11-16 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
BR112016000195A8
(pt)
|
2013-07-11 |
2019-12-31 |
Acea Biosciences Inc |
compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias
|
|
EA032757B1
(ru)
|
2014-02-14 |
2019-07-31 |
Экселиксис, Инк. |
Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
SG11201607990QA
(en)
|
2014-04-25 |
2016-11-29 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
EA033834B1
(ru)
|
2014-07-31 |
2019-11-29 |
Exelixis Inc |
Способ получения кабозантиниба, меченного фтором-18, и его аналогов
|
|
MA40457A
(fr)
|
2014-08-05 |
2017-06-14 |
Exelixis Inc |
Combinaison de médicaments pour traiter le myélome multiple
|
|
EP3187491A4
(en)
|
2014-08-28 |
2018-08-01 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
|
US20180028662A1
(en)
|
2015-02-25 |
2018-02-01 |
Eisai R&D Management Co., Ltd. |
Method for Suppressing Bitterness of Quinoline Derivative
|
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
|
ES2769124T3
(es)
*
|
2015-07-20 |
2020-06-24 |
Betta Pharmaceuticals Co Ltd |
Forma cristalina de maleato de derivados de piridina condensados y usos de la misma
|
|
WO2017011920A1
(en)
*
|
2015-07-22 |
2017-01-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Compounds and uses thereof in the treatment of cancers and other medical conditions
|
|
CN108135894B
(zh)
|
2015-08-20 |
2021-02-19 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
EP3359159B1
(en)
|
2015-10-09 |
2023-06-07 |
ACEA Therapeutics, Inc. |
Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
|
|
GB201520500D0
(en)
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
|
GB201520499D0
(en)
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
|
US11141413B2
(en)
|
2016-04-15 |
2021-10-12 |
Exelixis, Inc. |
Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
|
|
CN106496232B
(zh)
*
|
2016-09-22 |
2018-11-09 |
南方医科大学 |
一种具有抗肿瘤活性的1-(2-四氢吡喃)-1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法
|
|
CN110072528B
(zh)
|
2017-02-08 |
2022-04-26 |
卫材R&D管理有限公司 |
治疗肿瘤的药物组合物
|
|
AU2017408099A1
(en)
|
2017-04-07 |
2019-11-07 |
ACEA Therapeutics, Inc. |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
WO2018212202A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
WO2018228923A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
EP3638669A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
WO2018228925A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
EP3655406A1
(en)
|
2017-07-18 |
2020-05-27 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
CN118903436A
(zh)
|
2018-01-31 |
2024-11-08 |
德西费拉制药有限责任公司 |
治疗肥大细胞增多症的组合疗法
|
|
KR102708177B1
(ko)
|
2018-01-31 |
2024-09-23 |
데시페라 파마슈티칼스, 엘엘씨. |
위장관 기질 종양의 치료를 위한 병용 요법
|
|
TWI787523B
(zh)
|
2018-06-15 |
2022-12-21 |
漢達生技醫藥股份有限公司 |
達沙替尼十二烷基硫酸鹽之結晶
|
|
UY38349A
(es)
|
2018-08-30 |
2020-03-31 |
Array Biopharma Inc |
Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
|
|
US20220047603A1
(en)
|
2018-12-11 |
2022-02-17 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
ES2974634T3
(es)
|
2018-12-21 |
2024-06-28 |
Celgene Corp |
Inhibidores de tienopiridinas de RIPK2
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
IL330104A
(en)
|
2019-03-11 |
2026-08-01 |
Deciphera Pharmaceuticals Llc |
Crystalline forms of rifatinib
|
|
EP3990458A4
(en)
*
|
2019-06-25 |
2025-01-08 |
Sinopsee Therapeutics |
LINKS TO THE TREATMENT OF CANCER
|
|
US12691108B2
(en)
|
2019-08-12 |
2026-07-28 |
Deciphera Pharmaceuticals, Llc |
Methods for treating vascular malformations
|
|
HRP20260411T1
(hr)
|
2019-08-12 |
2026-05-08 |
Deciphera Pharmaceuticals, Llc |
Ripretinib za liječenje gastrointestinalnih stromalnih tumora
|
|
FI4084779T3
(fi)
|
2019-12-30 |
2024-12-16 |
Deciphera Pharmaceuticals Llc |
1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
WO2022167627A1
(en)
|
2021-02-05 |
2022-08-11 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN116836176B
(zh)
*
|
2022-03-23 |
2026-02-24 |
中国科学院上海药物研究所 |
青蒿素类化合物、其制备方法和应用
|
|
CN115160340B
(zh)
*
|
2022-06-07 |
2023-07-21 |
四川大学华西医院 |
一种具有ack1抑制活性的小分子化合物及其应用
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|
|
WO2024110606A1
(en)
*
|
2022-11-25 |
2024-05-30 |
Synthon B.V. |
A process for preparation of cabozantinib or tivozanib
|
|
KR20250136810A
(ko)
|
2023-01-31 |
2025-09-16 |
한다 온콜로지, 엘엘씨 |
개선된 카보잔티닙 조성물 및 사용 방법
|